CAR-T Forecast: Celgene Follows, But Also Leads As Next Batch Of T-Cell Therapies Near Market
Celgene's lead program will be the third autologous CD19-targeting T-cell therapy on the market, but the company is in the lead among BCMA-targeting CAR-T candidates. Next-generation technologies are also on the way.
You may also be interested in...
Public Company Edition: SpringWorks has the biggest IPO ambitions of recent US filers. Also, Deciphera raises $400m after good data and Protalix seeks strategic alternatives.
With no more activist investor challenge, shareholders of both companies overwhelmingly approved the deal. Bristol said it will have leading positions in oncology and cardiovascular disease, and gain five potential blockbusters in the Celgene buyout.
Draft national coverage decision addresses current indications and hospital sites of care. CMS expects to “leverage” existing FDA post-market data collection requirements but seeks additional data on patient-reported outcomes in some cases.